Allen S. Melemed Sells 3,065 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) insider Allen S. Melemed sold 3,065 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.50, for a total value of $13,792.50. Following the sale, the insider now owns 152,875 shares of the company's stock, valued at $687,937.50. The trade was a 1.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Chimerix Trading Up 14.9 %

NASDAQ:CMRX traded up $0.65 during trading hours on Tuesday, hitting $5.03. The company had a trading volume of 3,540,371 shares, compared to its average volume of 1,520,251. The company has a 50-day moving average of $3.60 and a 200 day moving average of $1.85. The company has a market cap of $452.49 million, a P/E ratio of -5.37 and a beta of 0.35. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $5.15.

Wall Street Analysts Forecast Growth

CMRX has been the subject of several research reports. Wedbush reiterated an "outperform" rating and set a $6.00 price target on shares of Chimerix in a research report on Tuesday, December 10th. HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of Chimerix in a report on Monday, December 30th.

Institutional Trading of Chimerix

Large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. grew its holdings in shares of Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after purchasing an additional 496,823 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares during the period. Peapod Lane Capital LLC purchased a new position in shares of Chimerix during the 4th quarter worth $2,626,000. Valeo Financial Advisors LLC grew its holdings in shares of Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock worth $509,000 after purchasing an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC purchased a new position in shares of Chimerix during the 4th quarter worth $221,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.